Fifteen Massachusetts biotechs went public in the first seven months of this year, surpassing the state’s total for all of 2017 and putting the white-hot sector on a potential record-setting pace, according to a new industry report.
Led by Rubius Therapeutics (RUBY), a Cambridge biotech created by Flagship Pioneering that raised about $277 million in an IPO this summer, the 15 companies attracted nearly $1.7 billion in investments through July, said the report, by the Massachusetts Biotechnology Council, a trade group.
